Astrid‐Helene Ravn Jørgensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Astrid‐Helene Ravn Jørgensen has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Simon Francis Thomsen
Department of Biomedical Sciences, Department of Dermatology Bispebjerg Hospital, University of Copenhagen Copenhagen Denmark
15 shared publications Simon Francis Thomsen
Department of Dermato‐Venereology & Wound Healing Centre Bispebjerg Hospital Copenhagen Denmark
9 shared publications- Yiqiu Yao
Department of Dermato-Venereology and Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark
9 shared publications - Hans Christian Ring
Department of Dermatology, Zealand University Hospital, Roskilde, Denmark
7 shared publications Hans Christian Ring
Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark
6 shared publicationsYiqiu Yao
Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark
6 shared publications
Latest Publications
- Open Access
- 13 September 2023
- Published by Wiley in JEADV Clinical Practice
- Vol. 2 (4) , 973-982
Disease‐ and treatment‐related expectations, attitudes, and beliefs among adult patients initiating or switching biological therapies for psoriasis
Background: The treatment expectations of patients with psoriasis are essential for clinical outcomes.Objectives: To examine disease‐ and treatment related intra‐ and interpersonal factors and their relation to treatment expectations among patients with psoriasis who initiate or switch biological therapy.Methods: Consecutive adult patients with moderate to severe psoriasis who initiated or switched biological therapy completed a questionnaire regarding their disease‐ and treatment‐related expectations. Additionally, they filled out Patients' Attitudes and Beliefs Scale (PABS), Trust in Physician Scale (TPS) and Dermatology Life Quality Index (DLQI) questionnaires. Psoriasis Area Severity Index (PASI) was scored before and 3 months after treatment initiation.Results: A total of 65 patients participated; 28% expected p = 0.026), higher PASI score (p = 0.004) and lower TPS score (p = 0.006) were associated with high overall expectations towards biological therapy. PABS scores were not significantly associated with high expectations. The proportion of patients having low expectations was greatest when asked about work/education, partner interaction and socializing. Additionally, high expectations towards these subjects were associated with higher DLQI (p = 0.047, p = 0.014 and p = 0.056, respectively). Patients with high overall expectations towards biological therapy had a significantly greater reduction in absolute PASI score following treatment (4.7 vs. 2.75), p = 0.048.Conclusions: Techniques aimed at maximizing patients' expectation‐effect (placebo response) should be implemented in daily clinical practice. Knowledge about gender, disease severity, impact on life quality and patients' trust in physician should be taken into consideration.
- 13 September 2023
- Published by Wiley in JEADV Clinical Practice
- Vol. 2 (4) , 973-982
Open AccessDisease‐ and treatment‐related expectations, attitudes, and beliefs among adult patients initiating or switching biological therapies for psoriasis
Background: The treatment expectations of patients with psoriasis are essential for clinical outcomes.Objectives: To examine disease‐ and treatment related intra‐ and interpersonal factors and their relation to treatment expectations among patients with psoriasis who initiate or switch biological therapy.Methods: Consecutive adult patients with moderate to severe psoriasis who initiated or switched biological therapy completed a questionnaire regarding their disease‐ and treatment‐related expectations. Additionally, they filled out Patients' Attitudes and Beliefs Scale (PABS), Trust in Physician Scale (TPS) and Dermatology Life Quality Index (DLQI) questionnaires. Psoriasis Area Severity Index (PASI) was scored before and 3 months after treatment initiation.Results: A total of 65 patients participated; 28% expected p = 0.026), higher PASI score (p = 0.004) and lower TPS score (p = 0.006) were associated with high overall expectations towards biological therapy. PABS scores were not significantly associated with high expectations. The proportion of patients having low expectations was greatest when asked about work/education, partner interaction and socializing. Additionally, high expectations towards these subjects were associated with higher DLQI (p = 0.047, p = 0.014 and p = 0.056, respectively). Patients with high overall expectations towards biological therapy had a significantly greater reduction in absolute PASI score following treatment (4.7 vs. 2.75), p = 0.048.Conclusions: Techniques aimed at maximizing patients' expectation‐effect (placebo response) should be implemented in daily clinical practice. Knowledge about gender, disease severity, impact on life quality and patients' trust in physician should be taken into consideration.
- 25 February 2023
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (6) , E321-E323
Characteristics of patients with hidradenitis suppurativa and concomitant inflammatory bowel disease
- 25 February 2023
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (6) , E321-E323
Characteristics of patients with hidradenitis suppurativa and concomitant inflammatory bowel disease
- Open Access
- 16 December 2022
- Published by Wiley in JEADV Clinical Practice
- Vol. 2 (1) , 80-91
Cluster analysis identifies six clinical subtypes of hidradenitis suppurativa characterised by distinct comorbidities, inflammatory and metabolic profiles, patient‐reported outcomes and treatment patterns
Background: Sub‐classification of hidradenitis suppurativa (HS) may allow for a better understanding of disease aetiology and disease burden, and eventually permit a more personalised treatment for patients.Objective: To identify patient subtypes of HS based on comorbidity patterns and clinical characteristics, and to examine their inflammatory and metabolic blood profiles and associated levels of experienced distress, pain, quality of life, employment status and prescribed treatments.Methods: Cluster analysis of clinical data from consecutive, newly referred adult HS patients attending a dermatological hospital department.Results: A total of 534 patients (338 women and 196 men) with a mean age of 40.5 years (SD = 13.7) were included; 35.4% had Hurley stage I, 50.4% had Hurley stage II, and 14.8% had Hurley stage III. In total, six disease subtypes were identified: ‘female subtype’ (n = 182, 34.1%), ‘familial subtype’ (n = 144, 27.0%), ‘diabetes subtype’ (n = 107, 20.0%), ‘psychiatric disease subtype’ (n = 49, 9.2%), ‘Crohn's disease subtype’ (n = 29, 5.4%) and ‘asthma subtype’ (n = 23, 4.3%). Patients with ‘Crohn's disease subtype’ and ‘diabetes subtype’ had highest levels of systemic inflammation (C‐reactive protein, erythrocyte sedimentation rate, leucocytes and neutrophils), blood glucose and lipids (triglycerides), p < 0.001. The highest boil‐associated pain score, p < 0.001, overall disease‐related distress, p = 0.008 and lowest quality of life, p = 0.015, was reported by patients with ‘familial subtype’, whereas highest rates of unemployment were observed among patients with ‘diabetes subtype’ and ‘psychiatric disease subtype’, p < 0.001. Treatment patterns differed significantly between the subtypes, with biologics being most often prescribed to patients with ‘Crohn's disease subtype’ (21.1%), p < 0.001.Conclusion: This study identified six subtypes of HS based on comorbidity patterns, clinical characteristics, blood profiles, patient‐reported outcomes and treatment patters, supporting the concept of heterogeneity within HS.
- 16 December 2022
- Published by Wiley in JEADV Clinical Practice
- Vol. 2 (1) , 80-91
Open AccessCluster analysis identifies six clinical subtypes of hidradenitis suppurativa characterised by distinct comorbidities, inflammatory and metabolic profiles, patient‐reported outcomes and treatment patterns
Background: Sub‐classification of hidradenitis suppurativa (HS) may allow for a better understanding of disease aetiology and disease burden, and eventually permit a more personalised treatment for patients.Objective: To identify patient subtypes of HS based on comorbidity patterns and clinical characteristics, and to examine their inflammatory and metabolic blood profiles and associated levels of experienced distress, pain, quality of life, employment status and prescribed treatments.Methods: Cluster analysis of clinical data from consecutive, newly referred adult HS patients attending a dermatological hospital department.Results: A total of 534 patients (338 women and 196 men) with a mean age of 40.5 years (SD = 13.7) were included; 35.4% had Hurley stage I, 50.4% had Hurley stage II, and 14.8% had Hurley stage III. In total, six disease subtypes were identified: ‘female subtype’ (n = 182, 34.1%), ‘familial subtype’ (n = 144, 27.0%), ‘diabetes subtype’ (n = 107, 20.0%), ‘psychiatric disease subtype’ (n = 49, 9.2%), ‘Crohn's disease subtype’ (n = 29, 5.4%) and ‘asthma subtype’ (n = 23, 4.3%). Patients with ‘Crohn's disease subtype’ and ‘diabetes subtype’ had highest levels of systemic inflammation (C‐reactive protein, erythrocyte sedimentation rate, leucocytes and neutrophils), blood glucose and lipids (triglycerides), p < 0.001. The highest boil‐associated pain score, p < 0.001, overall disease‐related distress, p = 0.008 and lowest quality of life, p = 0.015, was reported by patients with ‘familial subtype’, whereas highest rates of unemployment were observed among patients with ‘diabetes subtype’ and ‘psychiatric disease subtype’, p < 0.001. Treatment patterns differed significantly between the subtypes, with biologics being most often prescribed to patients with ‘Crohn's disease subtype’ (21.1%), p < 0.001.Conclusion: This study identified six subtypes of HS based on comorbidity patterns, clinical characteristics, blood profiles, patient‐reported outcomes and treatment patters, supporting the concept of heterogeneity within HS.
- Open Access
- 13 September 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (2) , 328-331.e3
Biomarkers of Tissue Turnover and Systemic Inflammation Are Associated with Disease Severity and Activity in Patients with Hidradenitis Suppurativa
- 13 September 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (2) , 328-331.e3
Open AccessBiomarkers of Tissue Turnover and Systemic Inflammation Are Associated with Disease Severity and Activity in Patients with Hidradenitis Suppurativa
- Open Access
- 8 March 2022
- Published by Wiley in Health Science Reports
- Vol. 5 (2) , e535
Decreased glomerular function is associated with disease severity in patients with hidradenitis suppurativa
- 8 March 2022
- Published by Wiley in Health Science Reports
- Vol. 5 (2) , e535
Open AccessDecreased glomerular function is associated with disease severity in patients with hidradenitis suppurativa
- 11 December 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (5) , E352-E354
Arthritis in patients with hidradenitis suppurativa
- 11 December 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (5) , E352-E354
Arthritis in patients with hidradenitis suppurativa
- 1 December 2021
- Vol. 19 (6) , 432-437
Anemia in Patients with Hidradenitis Suppurativa: Prevalence and Risk Factors in a Hospital-Based Cohort.
We examined the prevalence and risk factors of anemia in patients with hidradenitis suppurativa (HS). The presence of anemia and information on risk factors was obtained through interview, clinical examination, and blood samples in a cohort of 367 consecutive patients with HS. The overall prevalence of anemia was 9.3% (11.4% in men and 8.1% in women). Altogether 7.9%, 7.0%, and 20.4% of patients with Hurley stage I, II, and III were anemic, respectively. Risk factors for anemia included increasing age, nonwhite ethnicity, sporadic (nonfamilial) HS, concomitant inflammatory bowel disease (IBD), absence of hypertension, and absence of infected lesions in the preceding month. We found significant inverse correlations between hemoglobin level and inflammatory markers in the blood. There were significant correlations between hemoglobin and lipid levels, and between lipid levels and inflammatory markers. Hemoglobin levels are lower in patients with more severe HS and with more chronic inflammatory burden compared to those with less disease severity. Older age, nonwhite ethnicity, sporadic (nonfamilial) HS, and IBD are the risk factors of anemia.
- 1 December 2021
- Vol. 19 (6) , 432-437
Anemia in Patients with Hidradenitis Suppurativa: Prevalence and Risk Factors in a Hospital-Based Cohort.
We examined the prevalence and risk factors of anemia in patients with hidradenitis suppurativa (HS). The presence of anemia and information on risk factors was obtained through interview, clinical examination, and blood samples in a cohort of 367 consecutive patients with HS. The overall prevalence of anemia was 9.3% (11.4% in men and 8.1% in women). Altogether 7.9%, 7.0%, and 20.4% of patients with Hurley stage I, II, and III were anemic, respectively. Risk factors for anemia included increasing age, nonwhite ethnicity, sporadic (nonfamilial) HS, concomitant inflammatory bowel disease (IBD), absence of hypertension, and absence of infected lesions in the preceding month. We found significant inverse correlations between hemoglobin level and inflammatory markers in the blood. There were significant correlations between hemoglobin and lipid levels, and between lipid levels and inflammatory markers. Hemoglobin levels are lower in patients with more severe HS and with more chronic inflammatory burden compared to those with less disease severity. Older age, nonwhite ethnicity, sporadic (nonfamilial) HS, and IBD are the risk factors of anemia.
- Open Access
- 16 September 2021
- Published by Wiley in Health Science Reports
- Vol. 4 (3) , e360
Liver enzyme levels are associated with markers of systemic inflammation, disease severity, and metabolic syndrome in patients with hidradenitis suppurativa
- 16 September 2021
- Published by Wiley in Health Science Reports
- Vol. 4 (3) , e360
Open AccessLiver enzyme levels are associated with markers of systemic inflammation, disease severity, and metabolic syndrome in patients with hidradenitis suppurativa
- 4 March 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (7) , 785-791
Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study
Aim: To evaluate the clinical efficacy of tetracycline, doxycycline, and lymecycline in patients with hidradenitis suppurativa (HS).Methods: A prospective study of three different treatment regimens in patients with HS; oral tetracycline 500 mg twice daily, oral doxycycline 100 mg twice daily, and oral lymecycline 300 mg twice daily were administered in patients with HS. Outcomes were change in Hidradenitis Suppurativa Score (HSS), Dermatology Life Quality Life index (DLQI), overall disease‐related distress, boil‐related pain, number of boils in the preceding month, fraction of patients with no boils in the preceding month, and Physician's Global Assessment (PGA) score at follow‐up.Results: In total, 108 patients, 73 (67.6%) women and 35 (32.4%) men, were included. Mean duration of treatment was 4.3 months. The mean HSS at baseline was 26.10 (SD 20.18) points, improving to 17.97 (SD 17.88) at follow‐up, difference is 8.13 (95% CI 5.21–10.93), P < 0.0001. Highest improvement in HSS was observed in the tetracycline group. After multivariate adjustment, higher reduction in HSS was significantly associated with lower BMI, Hurley stage III, higher HSS at baseline, and higher number of boils in the preceding month at baseline.Conclusion: Oral treatment with tetracycline, doxycycline, and lymecycline appears effective and safe in HS patients. Tetracycline provided the greatest clinical improvement measured by HSS.
- 4 March 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (7) , 785-791
Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study
Aim: To evaluate the clinical efficacy of tetracycline, doxycycline, and lymecycline in patients with hidradenitis suppurativa (HS).Methods: A prospective study of three different treatment regimens in patients with HS; oral tetracycline 500 mg twice daily, oral doxycycline 100 mg twice daily, and oral lymecycline 300 mg twice daily were administered in patients with HS. Outcomes were change in Hidradenitis Suppurativa Score (HSS), Dermatology Life Quality Life index (DLQI), overall disease‐related distress, boil‐related pain, number of boils in the preceding month, fraction of patients with no boils in the preceding month, and Physician's Global Assessment (PGA) score at follow‐up.Results: In total, 108 patients, 73 (67.6%) women and 35 (32.4%) men, were included. Mean duration of treatment was 4.3 months. The mean HSS at baseline was 26.10 (SD 20.18) points, improving to 17.97 (SD 17.88) at follow‐up, difference is 8.13 (95% CI 5.21–10.93), P < 0.0001. Highest improvement in HSS was observed in the tetracycline group. After multivariate adjustment, higher reduction in HSS was significantly associated with lower BMI, Hurley stage III, higher HSS at baseline, and higher number of boils in the preceding month at baseline.Conclusion: Oral treatment with tetracycline, doxycycline, and lymecycline appears effective and safe in HS patients. Tetracycline provided the greatest clinical improvement measured by HSS.
- Open Access
- 1 February 2021
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 112 (2) , 153-158
Métodos referidos por los pacientes para aliviar el dolor asociado a la hidradenitis supurativa
- 1 February 2021
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 112 (2) , 153-158
Open AccessMétodos referidos por los pacientes para aliviar el dolor asociado a la hidradenitis supurativa